Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer.

Cureus · 2023 · PMC10512434 · PMID 37745737

Europe PMC DOI

hedged sentence

0.7400

closest p · 14.8× alpha

0.7400

boldest claim

The sentences

did not reach statistical significancep=0.740not close (p > 0.1)

The IR-NMIBC group exhibited a higher median DFS (44 months, 95% CI 27.0-61.0) than the HR-NMIBC group (39 months, 95% CI 22.0-56.0), although this difference did not reach statistical significance (p=0.740).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.